Navigation Links
Dynasil Corporation of America Reports Fiscal Year 2013 Financial Results

WATERTOWN, Mass., Dec. 20, 2013 /PRNewswire/ -- Dynasil Corporation of America (NASDAQ: DYSL), a developer of sensing, detection and analysis technology for homeland security, medical and industrial applications, today announced financial results for fiscal year ended September 30, 2013 and the filing of its Annual Report on Form 10-K.

Revenues for the fiscal year ended September 30, 2013 were $42.8 million. This represents a decrease of $5.1 million or 10.6% over revenues for the fiscal year ended September 30, 2012 of $47.9 million. 

Gross profit for fiscal 2013 totaled $18.1 million, or 42.3% of net revenue, compared with $19.5 million, or 40.7% of revenue for fiscal 2012.  Gross profit margin improved primarily as a result of higher gross margins in the Contract Research segment partially offset by a decrease in the Instruments segment.

Selling, general and administrative expenses decreased $1.5 million to $19.4 million or 45.4% of sales in fiscal year 2013, from $20.9 million or 43.7% of sales for fiscal year 2012.  SG&A expenses decreased primarily as a result of the substantial completion of the engineering costs associated with the product refreshes in our Instruments segment.

The Instruments segment had the greatest decrease in SG&A costs, decreasing $1.6 million to $3.5 million in 2013 compared to $5.1 million in 2012.  This segment had two main product lines: a hand-held lead paint analyzer and a medical gamma probe used primarily in breast cancer treatment. The Company began a product refresh on both product lines in 2012 to enhance them with new features and functionality to maintain their market positions.  The Company spent $1.3 million in fiscal year 2012 on research and development on the products and significant additional amounts on sales and marketing efforts in advance of the new product launches. In fiscal year 2013, these costs and other SG&A costs were substantially reduced while awaiting regulatory approval. 

The Company's updated medical probe, the Navigator 2.0, was approved for sale in May of 2013.
However, as a result of the delays associated with both product line updates and an internal review of strategic alternatives for the lead paint analyzer product, the Company performed an interim impairment test of the Instrument segment and recorded an impairment of goodwill and intangibles totaling $6.8 million in the quarter ending March 31, 2013.

"As reported previously, we are making important steps in right-sizing our business, reducing outstanding indebtedness, and eliminating cost.  With the spin out of our tissue sealant technology to the newly-formed subsidiary, Xcede Technologies, Inc. in October and the divestiture of our XRF product line in November, we continue to make significant improvements to our cash flows and our balance sheet," said Peter Sulick, Chairman and CEO of Dynasil.
"Going forward, we are focused on improving our liquidity and pursuing strategic initiatives that best position the company for future profitable growth."

Including the goodwill impairment charge, net loss for the 12 months ended September 30, 2013 was $8.7 million, or $0.59 per share, compared with a loss of $4.3 million, or $0.29 per share, in fiscal 2012.

Liquidity On December 31, 2012, the Company announced it was in default of certain financial covenants set forth in the terms of its outstanding indebtedness with respect to its fiscal year ended September 30, 2012.
We continued to be in default throughout our fiscal year ended September 30, 2013 and currently remain in default.  As a result, our lenders have the ability to require immediate payment of all indebtedness under our loan agreements.  While the lenders have not exercised this right, their ability to require immediate payment has caused all of our outstanding indebtedness to be accelerated to current classification in our consolidated financial statements.

The Company has made all principal and interest payments due to its senior lender through the date of this filing.  In addition to making the required principal payments of approximately $1.9 million during fiscal year 2013, the Company also repaid an additional $300,000 of principal in connection with the contribution of its tissue sealant intellectual property to Xcede Technologies, Inc., a joint venture with Mayo Clinic formed on or about October 1, 2013 to spin out and separately fund the development of the tissue sealant technology.  Xcede has initiated financing efforts and has received funding from internal sources and outside investors.

The Company has accrued but not remitted monthly interest payments to its subordinated lender since February 2013 and does not expect to resume interest payments to its subordinated lender until it resolves its default with the senior lender.Subsequent to fiscal year-end, the Company also repaid approximately $1.25 million of principal to its senior lender from the proceeds received from the sale of its lead paint business included in the Instruments segment.  Management is continuing to pursue potential other sales transactions which, if consummated, would result in additional principal payments to the bank and also expects to continue discussions with its lenders to address the financial covenant situation.  Because of the continuing default of the financial covenants and the possibility of an acceleration of the indebtedness by the lenders, the Company has classified all its outstanding indebtedness as a current liability in the accompanying consolidated balance sheets.

Given the Company's results and the uncertainty created by the defaults under the outstanding indebtedness, the Company's independent registered public accounting firm has included a "going concern" explanatory paragraph in its audit opinion for the year ended September 30, 2013.

About DynasilDynasil Corporation of America (NASDAQ: DYSL) develops and manufactures detection and analysis technology, precision instruments and optical components for the homeland security, medical and industrial markets.  Combining world-class technology with expertise in research and materials science, Dynasil is commercializing products including dual-mode radiation detection solutions for Homeland Security and commercial applications, and sensors for non-destructive testing.  The Company is building a relationship with the Mayo Clinic to develop early-stage opportunities such as advanced biomedical technologies. Dynasil has an impressive and growing portfolio of issued and pending U.S. patents.  The Company is based in Watertown, Massachusetts, with additional operations in Mass., Minn., NY, NJ and the United Kingdom. More information about the Company is available at

Forward-looking Statements
This press release may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995.  These forward-looking statements regarding future events and our future results are based on current expectations, estimates, forecasts, and projections and the beliefs and assumptions of our management, including, without limitation, our expectations regarding results of operations, our default under the financial covenants under our loan agreement with Santander Bank and Massachusetts Capital Resource Company, Xcede obtaining financing from outside investors, the commercialization of our products including our dual mode detectors, our development of new technologies including at Dynasil Biomedical, the adequacy of our current financing sources to fund our current operations, our growth initiatives, our capital expenditures and the strength of our intellectual property portfolio.  These forward-looking statements may be identified by the use of words such as "plans", "intends," "may," "could," "expect," "estimate," "anticipate," "continue" or similar terms, though not all forward-looking statements contain such words.  The actual results of the future events described in such forward‑looking statements could differ materially from those stated in such forward‑looking statements due to a number of important factors. These factors that could cause actual results to differ from those anticipated or predicted include, without limitation, our ability to resolve our current default under our outstanding indebtedness,  our ability to develop and commercialize our products, including obtaining regulatory approvals, the size and growth of the potential markets for our products and our ability to serve those markets, the rate and degree of market acceptance of any of our products, our ability to address our material weaknesses in our internal controls, general economic conditions, costs and availability of raw materials and management information systems, our ability to obtain and maintain intellectual property protection for our products, competition, the loss of key management and technical personnel, our ability to obtain timely payment of our invoices to governmental customers, litigation, the effect of governmental regulatory developments, the availability of financing sources, our ability to deleverage our balance sheet, our ability to identify and execute on acquisition opportunities and integrate such acquisitions into our business, and seasonality, as well as the uncertainties set forth in the Company's Annual Report on Form 10 K and from time to time in the Company's other filings with the Securities and Exchange Commission. The Company disclaims any intention or obligation to update any forward-looking statements, whether as a result of new information, future events or otherwise.

Patty Kehe
Corporate Secretary
Dynasil Corporation of America
Phone: 617.668.6855

2013September 30,
2012Current AssetsCash and cash equivalents

3,414,880Accounts receivable, net

3,657,3205,475,142Costs in excess of billings and unbilled receivables

1,537,3181,735,798Inventories, net of reserves

3,140,2443,271,700Prepaid expenses and other current assets

1,291,9421,460,836Total current assets

12,063,65215,358,356Property, Plant and Equipment, net

4,773,7794,984,150Other AssetsIntangibles, net


6,240,98310,254,160Deferred financing costs, net

114,229165,457Total other assets

9,839,79517,122,922Total Assets$
37,465,428LIABILITIES AND STOCKHOLDERS' EQUITYCurrent LiabilitiesCurrent portion of long-term debt

,984,492Capital lease obligations, current

124,383-Accounts payable

2,056,2622,416,397Deferred revenue

515,790694,672Accrued expenses and other liabilities

2,846,8502,809,580Total current liabilities

15,362,33317,905,141Long-term LiabilitiesCapital lease obligations, net of current portion

232,173-Pension liability

249,966345,443Deferred tax liability

186,866371,256Total long-term liabilities

669,005716,699Stockholders' Equity

10,645,88818,843,588Total Liabilities and Stockholders' Equity$

47,887,150Cost of revenue24,667,08728,381,407Gross profit18,085,74519,505,743Operating expenses:Sales and marketing expenses1,746,8651,729,703Research and development expenses2,307,4072,810,778General and administrative expenses15,371,49416,386,454Impairment of goodwill and long-lived assets6,829,0722,284,499Total operating expenses26,254,83823,211,434Loss from operations(8,169,093)(3,705,691)Interest expense, net861,038639,096Loss before income taxes(9,030,131)(4,344,787)Income tax credit(302,960)(41,021)Net loss$
(4,303,766)Net loss$
(4,303,766)Other comprehensive loss:(Increase) decrease in pension liability$
(345,443)Foreign currency translation(1,734)109,783Total comprehensive loss$
(4,539,426)Basic net loss per common share$
(0.29)Diluted net loss per common share$
(0.29)Weighted average shares outstandingBasic14,812,85814,811,294Diluted14,812,85814,811,294 

SOURCE Dynasil Corporation of America
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Dynasil Corporation of America Reports Third Quarter Fiscal 2013 Financial Results
2. Precision Optics Corporation Announces $1 Million Order for Microprecision™ Based Endoscopes
3. CVS Caremark Corporation to Hold First Quarter 2012 Conference Call
4. Richard Wolf Medical Instruments Corporation: 40 Years of Innovation
5. Haemonetics Signs Definitive Agreement to Acquire Pall Corporations Blood Collection, Filtration and Processing Product Lines For $551 Million
6. Luminex Corporation Reports First Quarter 2012 Results
7. ShangPharma Corporation Files 2011 Annual Report on Form 20-F
8. Techne Corporation Releases Unaudited Third Quarter and Nine Month Fiscal Year 2012 Results
9. Without Environmental Hygiene, Hand Hygiene Programs Fall Short in Reducing HAIs in Hospital Settings, Says UMF Corporation
10. Cara Therapeutics Licenses Novel Kappa Opioid Agonist, CR845, to Chong Kun Dang Pharmaceutical Corporation For South Korean Market
11. DURECT Corporation Announces First Quarter 2012 Financial Results and Update of Programs
Post Your Comments:
(Date:10/9/2015)... LAUSANNE , Schweiz, October 9, 2015 Der ... geht an Dr.   Yutaka Kondo und Dr.   ... JCA-Mauvernay Award   2015 " geht an Dr.   ... --> Der " JCA-Mauvernay Award   ... und Dr.   Junko Takita    ™ ...
(Date:10/8/2015)... England and PITTSBURGH , ... ), a leading global pharmaceutical company, will host a ... at 5:00 pm ET to review the value ... (NYSE: PRGO ; TASE) through Mylan,s offer to ... a comprehensive presentation which outlines the compelling proposition for ...
(Date:10/8/2015)... , Oct. 8, 2015  The National Heart, ... $40 million to the Broad Institute of MIT ... of 20,000 individuals, as well as data to ... profiling. Trans-Omics for Precision Medicine ... toward a larger initiative, which will use whole ...
Breaking Medicine Technology:
... Cephalon, Inc. (Nasdaq: CEPH ) today provided notice ... Notes due 2014 (the "2014 Notes") and 2.00 percent ... in respect of the Merger (as defined below) of ... Industries Ltd., an Israeli corporation ("Parent"), the consummation of ...
... The Plasma Protein Therapeutics Association (PPTA) ... temporary and proposed regulations implementing the ... and fails to take into account concerns expressed ... narrow definition of an "orphan drug" disproportionally affects ...
Cached Medicine Technology:
(Date:10/10/2015)... FLA. (PRWEB) , ... October 10, 2015 , ... In ... has been named the Best Place To Work in Jacksonville, amongst medium-sized companies with ... September 27th and was followed up with a celebratory gala on October 1st. ...
(Date:10/9/2015)... Los Angeles, CA (PRWEB) , ... October 09, 2015 , ... ... awareness for breast cancer victims, survivors, and the ongoing effort to find a cure. ... patients another outlet for helping women in need. With their Bra Collection Campaign, Beverly ...
(Date:10/9/2015)... ... ... Smoke alarms can save lives. In fact, according to the National Fire ... home fires in half. As part of Fire Prevention Week, Amica Insurance ... , Half of home fire deaths result from fires reported between 11 p.m. and ...
(Date:10/9/2015)... (PRWEB) , ... October 09, 2015 , ... ... company, has announced the final product specifications for TRACTUS, the world’s first sterile ... in the United States in response to the FDA’s recent Unique Device Identifier ...
(Date:10/9/2015)... ... October 09, 2015 , ... Cambias Insurance Agency, a family ... initiating a combined charity effort with Animal Rescue New Orleans in an effort ... , Animal Rescue New Orleans is a non-profit organization committed to rescuing and ...
Breaking Medicine News(10 mins):
... so does survival, study finds , MONDAY, Feb. 8 (HealthDay ... with increased risk of death, researchers say. , In a ... again at age 89 in a group of 555 participants ... at 85 and 89 years, and a greater decline in ...
... ... Strash, FACHE, Chief Executive Officer with Oro Valley Hospital, on critical issues facing healthcare ... ... timely communication among different segments of the medical community, Jackson & Coker ( ...
... , CINCINNATI , Feb. 8 Three ... "about right," according to a study of more than 65,000 ... of obesity over the past several years, the number of ... 1999 and 2007," says Nicholas M. Edwards , MD, ...
... triggering bone formation , MONDAY, Feb. 8 (HealthDay News) -- ... osteoporosis in lab mice and rats, a new study has ... gut hinders bone formation. Most current drugs for osteoporosis only ... "New therapies that inhibit the production of serotonin in the ...
... BETHESDA, Md. , Feb. 8 /PRNewswire-Asia/ ... Western healthcare,products and services in the People,s Republic of China , today ... , , Financial Highlights:, -- Revenue in ... over year to $46.5 million;, -- Net ...
... ... McDonald, have formed One2One Partners. The firm creates customized programs that strengthen the relationship ... an engaged workforce and minimize the threat of third-party intervention, regardless of potential legislation ... ...
Cached Medicine News:
... Resistant Tips offer a safe alternative to ... designed for applications such as PCR(a), pipetting ... ART Tips are excellent for tissue culture, ... ART Tips prevent aerosol contaminants and liquids ...
Diamond Filter Tips play a critical role in preventing aerosol-borne contamination. Also available sterilized (no need to autoclave) and certified free of detectable RNase, DNase, DNA, RNA, and prote...
... Eliminate aerosol contamination, which ... in PCR. Hydrophobic, nonwicking ... air can pass through ... in contrast to tips ...
Dnase-free, with an integral filter to protect against carry over and contamination from aerosols...
Medicine Products: